MedTrace Logo

Effect of Prevnar 13 on Ear Infections in Children

NCT01199016 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 239

Last updated 2017-03-01

Study results available
· View outcomes & findings →

Summary

Prevnar (7 valent pneumococcal conjugate vaccine \[7vPnC\]) has been shown to be effective against ear infections in children. Prevnar 13 is a new vaccine that is similar to Prevnar. It is expected that the effectiveness of Prevnar 13 against ear infections in children will be similar to that observed following Prevnar. Pfizer has committed to conduct a postmarketing study of the impact of Prevnar 13 in reducing ear infections among children.

Conditions

  • Otitis Media

Interventions

PROCEDURE

Tympanocentesis

To be performed as needed on children presenting with acute otitis media

PROCEDURE

Nose/throat swab

To be performed at every study visit

BIOLOGICAL

Observational

Observational Study Only

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
6 Months
Max Age
30 Months
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-09-30
Primary Completion
2016-01-31
Completion
2016-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01199016 on ClinicalTrials.gov